IGF-1R
Cross-source consensus on IGF-1R from 1 sources and 4 claims.
1 sources · 4 claims
How it works
Benefits
Evidence quality
Highlighted claims
- IGF-1R activates downstream oncogenic pathways including PI3K, Akt, and mTOR. — An Analytical Approach for Insulin-like Growth Factor Receptor 1 and Mammalian Target of Rapamycin Blockades in Ewing Sarcoma
- IGF-1R has a documented role in Ewing sarcoma. — An Analytical Approach for Insulin-like Growth Factor Receptor 1 and Mammalian Target of Rapamycin Blockades in Ewing Sarcoma
- Targeting IGF-1R has inhibited Ewing sarcoma cell growth in vitro and in xenograft models. — An Analytical Approach for Insulin-like Growth Factor Receptor 1 and Mammalian Target of Rapamycin Blockades in Ewing Sarcoma
- IGF-1R inhibition alone has produced low clinical response rates. — An Analytical Approach for Insulin-like Growth Factor Receptor 1 and Mammalian Target of Rapamycin Blockades in Ewing Sarcoma